Brief: Ardelyx Announces Acceptance Of New Drug Application For Tenapanor For Hyperphosphatemia In China
13/07/2023 14:27
July 13 (Reuters) - Shanghai Fosun Pharmaceutical Group
Co Ltd 600196.SS :
* ARDELYX ANNOUNCES ACCEPTANCE OF NEW DRUG APPLICATION FOR
TENAPANOR FOR HYPERPHOSPHATEMIA IN CHINA
* ARDELYX INC - POTENTIAL APPROVAL OF NDA SUBMISSION IN
CHINA IS
EXPECTED BY END OF 2024
Source text for Eikon: ID:nGNX1hNWVQ
Further company coverage: 600196.SS
Recent news on Ardelyx
See all newsArdelyx, Inc. reports results for the quarter ended June 30 - Earnings Summary
Ardelyx says Q2 product revenue at record high but IBSRELA revenue below expectations
Brief: Ardelyx Q2 Product Sales USD 118.129 Million
Ardelyx Q1 product revenue rises 38% on IBSRELA growth
Brief: Ardelyx Q1 Product Sales USD 93.373 Million